Exelixis
EXEL
$23.86
Share price
0.68%
Change (1 day)
30.38%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Market capitalization of Exelixis (EXEL)
Market cap: $7.03 Billion
As of April 2024 Exelixis has a market cap of $7.03 Billion. This makes Exelixis the world's 2103th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Exelixis from 2001 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $7.03 B | -5.71% |
| 2023 | $7.46 B | 44.19% |
| 2022 | $5.17 B | -10.54% |
| 2021 | $5.78 B | -7.11% |
| 2020 | $6.22 B | 16.3% |
| 2019 | $5.35 B | -9.24% |
| 2018 | $5.89 B | -34.42% |
| 2017 | $8.99 B | 108.06% |
| 2016 | $4.32 B | 236.22% |
| 2015 | $1.28 B | 355.78% |
| 2014 | $0.28 B | -75.06% |
| 2013 | $1.13 B | 34.75% |
| 2012 | $0.83 B | 30.78% |
| 2011 | $0.64 B | -28.46% |
| 2010 | $0.89 B | 12.81% |
| 2009 | $0.79 B | 50.04% |
| 2008 | $0.53 B | -41.36% |
| 2007 | $0.90 B | 4.63% |
| 2006 | $0.86 B | 9.96% |
| 2005 | $0.78 B | 10.28% |
| 2004 | $0.71 B | 41.74% |
| 2003 | $0.50 B | 5.8% |
| 2002 | $0.47 B | -49.09% |
| 2001 | $0.93 B |
End of Day market cap according to different sources
On Apr 28th, 2024 the market cap of Exelixis was reported to be:
$7.18 Billion
$6.98 Billion
$6.98 Billion
$6.98 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $353.37 B | 4,923.80% | 🇺🇸 USA |
 Pfizer PFE | $145.69 B | 1,971.35% | 🇺🇸 USA |
 Amgen AMGN | $145.64 B | 1,970.57% | 🇺🇸 USA |
 Sanofi SNY | $122.81 B | 1,646.01% | 🇫🇷 France |
 Merck MRK | $332.91 B | 4,633.00% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $91.70 B | 1,203.69% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $85.17 B | 1,110.90% | 🇬🇧 UK |
 Curis CRIS | $84.87 M | -98.79% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $0.52 B | -92.59% | 🇺🇸 USA |